Tiffany joined NEA in 2020 as part of the life sciences team where she has a focus in medtech, healthtech, and innovations that sit at the intersection of technology and life sciences. She currently serves as a Board Director on Relievant and FIRE1 (Foundry Incubator), and observes on the board of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, and Willow.

Previously, Tiffany was at Kaiser Permanente Ventures where she focused on investments across digital health, medical devices, and healthcare services. Prior to KPV, she was a Senior Life Sciences Consultant at L.E.K. Consulting in their Los Angeles and London offices working with biotech, life sciences, and private equity clients leading projects spanning M&A, portfolio optimization, and launch and commercialization strategy. At L.E.K., she had particular expertise in oncology, allergy/immunology, precision medicine, diagnostics, and orphan indications. Tiffany has also collaborated on research leveraging brain organoid and synthetic biology models to interrogate Alzheimer’s Disease, and has had prior experience at GE Ventures and Amgen.

Tiffany received a BA in Business Economic Theory from the University of California, Los Angeles and an MBA from Harvard Business School.